The identification of PabB protein as an essential metabolic drug target, coupled with screening of FDA-approved drugs as inhibitors, provides a promising framework for anti tubercular drug discovery.
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major global health crisis, aggravated by rapid emergence of multidrug-resistant (MDR) and extensively drug resistant (XDR) strains. Conventional drug discovery is time-consuming and expensive, making computational target identification and drug repurposing as crucial strategies to accelerate the development of novel anti-tubercular therapies. This study aimed to identify and prioritize the metabolic enzymes as potential drug targets through pathway based analysis and to screen the FDA-approved drug library for potential canidates for drug repurposing. Based on the pathway analysis, para-aminobenzoate synthase component I (PabB) was selected as a potential drug target owing to its role in folate biosynthesis. Subesquently, an FDA-approved drug library was screened based on ADMET properties and selected compounds were used for molecular docking agaist the protein. Molecular docking through DiffDock and validation using GNINA revealed that Ligand 5 and Ligand 27 exhibit favourable interaction profiles within the binding region of PabB, and emerged as potential candidates for further investigation in drug repurposing. The identification of PabB protein as an essential metabolic drug target, coupled with screening of FDA-approved drugs as inhibitors, provides a promising framework for anti tubercular drug discovery.
The rapid rise of multidrug‐resistant (MDR) Klebsiella pneumoniae has created a major global health challenge due to the limited availability of conserved therapeutic targets effective across diverse resistant strains. In this study, an integrative computational target‐discovery and drug‐repurposing framework was appli...
Manasi Bora, Prokriti Paul, S. Rajkhowa et al.· International Journal of Mic...· 0 citations
Findings support MurX as a viable therapeutic target and Bergenin as a promising candidate for further anti-TB drug development, and lays the foundation for subsequent experimental validation and the design of novel therapeutics targeting resistant strains of Mtb.
Mycobacterium tuberculosis (Mtb) caused disease Tuberculosis (TB) continues to be one of the leading causes of mortality although decades of medical research has progressed. With the alarming rise in multidrug-resistant and extensively drug-resistant strains, the effectiveness of conventional therapeutic regimens is be...
N. Parvin, K. Chanda, M. Balamurali· Biochemistry and Biophysics...· 0 citations
Computational phytochemistry represents a promising and cost-effective strategy for prioritizing phytochemicals against MDR/XDR-TB and offers a viable path for the revelation and development of unprecedented natural product-based anti-TB medications.
D. Sahu, B. Sahoo, Ashirbad Nanda et al.· Recent Advances in Anti-Infe...· 0 citations
This work constructed photo-cross-linker probes containing a minimalist diazirine and an alkynyl handle of four TB drugs─pretomanid, linezolid, moxifloxacin, and one newly identified inhibitor, BB2-50F, with diverse chemical structures and mechanisms of action and validated that these probes retain on-target activity a...
Li-Yan Huang, Kang Duan, C. Adolph et al.· ACS Infectious Diseases· 0 citations
Tuberculosis, one of the leading causes of mortality across the globe remains a prominent challenge and continues to affect the quality of lives of millions of people. Long treatment duration, improper prescription practices and premature discontinuation of therapy have led to the emergence of multi-drug resistant (MDR...
Barla Juli, Ayyagari Bhavyasri, Nekkala Charishma et al.· International journal of res...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.